What is EndoPredict®? 

EndoPredict® is a second-generation genomic prognostic test to optimize and individualize breast cancer treatment 

When to test?

Why test?

The EndoPredict® report helps physicians to answer the following questions: 

  • What is the risk of cancer recurrence? 
  • Will chemotherapy be beneficial? 
  • Can extended Chemotherapy be avoided? 
  • Can extended endocrine therapy be avoided?  


International Guidelines

Sample requirements

Formalin-Fixed Paraffin-Embedded (FFPE) sections, slides, or blocks 

  • Blocks must have a portion of the lesion with ≥30% invasive tumor on the diagnostic H&E slide  
  • Tissue Biopsy: >50% invasive tumor, with at least 20 µm of remaining unstained tissue for testing
  • In cases where blocks are not available: 
    • 1 x 3-5 µm H&E slide and 5 consecutive 10 µm unstained slides
  • Samples frozen prior to fixation are not appropriate for analysis. 

Report Features 

EndoPredict® provides a comprehensive and easy-to-read report that will help inform long-term therapeutic decisions, preventing unnecessary and costly chemotherapy and or endocrine therapy.  

Details contained in the report include: 

  • Patient clinical information
    • EPclin risk score
    • EPclin risk class 
  • Risk of recurrence
    • 10-year  
    • 5–15-year risk of recurrence after 5 years of endocrine therapy* 
  • Individual risk estimate 
  • Chemotherapy
    • Absolute benefit
    • Individual benefit 
  • Prognostic reports
    • 10-year
    • 5–15-year 

*Applies to patients who are distant-recurrence free after 5 years of endocrine therapy alone. 

Patient and Physician counseling

Specialized genetic counseling is available to physicians and patients through Counselomix. 

  • Licensed counselors 
  • Available globally through our online platform 
  • Available in multiple languages

For additional testing and counseling services, please contact us for more information.